{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T16:01:39Z","timestamp":1787068899960,"version":"build-2736575974"},"reference-count":103,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":3440,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2006,4]]},"DOI":"10.1002\/hep.21146","type":"journal-article","created":{"date-parts":[[2006,3,23]],"date-time":"2006-03-23T18:46:57Z","timestamp":1143139617000},"page":"661-672","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":144,"title":["The clinical and physiological spectrum of interferon\u2010alpha induced thyroiditis"],"prefix":"10.1097","volume":"43","author":[{"given":"Jamie C.","family":"Mandac","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonal","family":"Chaudhry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth E.","family":"Sherman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaron","family":"Tomer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-6-20241201","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1073\/pnas.91.4.1198","article-title":"Cytokine therapeutics: lessons from interferon alpha","volume":"91","author":"Gutterman","year":"1994","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R2-6-20241201","first-page":"2489","article-title":"Biological properties of recombinant alpha\u2010interferons: 40th anniversary of the discovery of interferons","volume":"58","author":"Pfeffer","year":"1998","journal-title":"Cancer Res"},{"key":"R3-6-20241201","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1097\/00001622-200311000-00005","article-title":"Interferons: mechanisms of action and clinical applications","volume":"15","author":"Parmar","year":"2003","journal-title":"Curr Opin Oncol"},{"key":"R4-6-20241201","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1634\/theoncologist.6-1-34","article-title":"Interferon in oncological practice: review of interferon biology, clinical applications, and toxicities","volume":"6","author":"Jonasch","year":"2001","journal-title":"Oncologist"},{"key":"R5-6-20241201","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1001\/jama.1991.03470100067035","article-title":"The interferons. Mechanisms of action and clinical applications","volume":"266","author":"Baron","year":"1991","journal-title":"JAMA"},{"key":"R6-6-20241201","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1016\/S0140-6736(01)06102-5","article-title":"Peginterferon alfa\u20102b plus ribavirin compared with interferon alfa\u20102b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial","volume":"358","author":"Manns","year":"2001","journal-title":"Lancet"},{"key":"R7-6-20241201","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1056\/NEJMoa020047","article-title":"Peginterferon alfa\u20102a plus ribavirin for chronic hepatitis C virus infection","volume":"347","author":"Fried","year":"2002","journal-title":"N Engl J Med"},{"key":"R8-6-20241201","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1016\/S0016-5085(03)00394-9","article-title":"Side effects of therapy for chronic hepatitis C","volume":"124","author":"Russo","year":"2003","journal-title":"Gastroenterology"},{"key":"R9-6-20241201","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1210\/jcem-63-5-1086","article-title":"Thyroid autoimmunity in patients on long term therapy with leukocyte\u2010 derived interferon","volume":"63","author":"Burman","year":"1986","journal-title":"J Clin Endocrinol Metab"},{"key":"R10-6-20241201","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1016\/S0140-6736(85)92475-4","article-title":"Primary hypothyroidism associated with interferon therapy of breast cancer","volume":"1","author":"Fentiman","year":"1985","journal-title":"Lancet"},{"key":"R11-6-20241201","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1089\/105072503322238809","article-title":"Interferon\u2010alpha and autoimmune thyroid disease","volume":"13","author":"Prummel","year":"2003","journal-title":"Thyroid"},{"key":"R12-6-20241201","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1089\/thy.1997.7.891","article-title":"Interferon\u2010alpha induced thyroid dysfunction: three clinical presentations and a review of the literature","volume":"7","author":"Koh","year":"1997","journal-title":"Thyroid"},{"key":"R13-6-20241201","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1016\/S0002-9343(96)00259-8","article-title":"Multiple changes in thyroid function in patients with chronic active HCV hepatitis treated with recombinant interferon\u2010alpha","volume":"101","author":"Roti","year":"1996","journal-title":"Am J Med"},{"key":"R14-6-20241201","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1530\/eje.0.1320587","article-title":"Autoimmunity and thyroid function in patients with chronic active hepatitis treated with recombinant interferon alpha\u20102a","volume":"132","author":"Preziati","year":"1995","journal-title":"Eur J Endocrinol"},{"key":"R15-6-20241201","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1053\/jhep.2002.36495","article-title":"Recombinant alfa\u2010interferon plus ribavirin therapy in children and adolescents with chronic hepatitis C","volume":"36","author":"Wirth","year":"2002","journal-title":"HEPATOLOGY"},{"key":"R16-6-20241201","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1007\/BF03345087","article-title":"Temporal relationship between the appearance of thyroid autoantibodies and development of destructive thyroiditis in patients undergoing treatment with two different type\u20101 interferons for HCV\u2010related chronic hepatitis: a prospective study","volume":"25","author":"Mazziotti","year":"2002","journal-title":"J Endocrinol Invest"},{"key":"R17-6-20241201","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1089\/105072502760258730","article-title":"Graves' ophthalmopathy associated with interferon\u2010alpha treatment for hepatitis C","volume":"12","author":"Villanueva","year":"2002","journal-title":"Thyroid"},{"key":"R18-6-20241201","first-page":"221","article-title":"Thyroid gland dysfunctions during antiviral therapy of chronic hepatitis C","volume":"7","author":"Kryczka","year":"2001","journal-title":"Med Sci Monit"},{"key":"R19-6-20241201","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1016\/j.autrev.2004.03.003","article-title":"Interferon induced Autoimmune Thyroid Disease (AITD): a model for human autoimmunity","volume":"3","author":"Oppenheim","year":"2004","journal-title":"Autoimmun Rev"},{"key":"R22-6-20241201","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1006\/clin.1997.4412","article-title":"Epidemiology and estimated population burden of selected autoimmune diseases in the United States","volume":"84","author":"Jacobson","year":"1997","journal-title":"Clin Immunol Immunopathol"},{"key":"R23-6-20241201","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1210\/jcem.87.2.8182","article-title":"Serum TSH, T(4), and thyroid antibodies in the United States population (1988 to 1994): National Health and Nutrition Examination Survey (NHANES III)","volume":"87","author":"Hollowell","year":"2002","journal-title":"J Clin Endocrinol Metab"},{"key":"R24-6-20241201","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1086\/378588","article-title":"Common and unique susceptibility loci in Graves and Hashimoto diseases: Results of whole\u2010genome screening in a data set of 102 multiplex families","volume":"73","author":"Tomer","year":"2003","journal-title":"Am J Hum Genet"},{"key":"R25-6-20241201","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1210\/er.2002-0030","article-title":"Searching for the autoimmune thyroid disease susceptibility genes: From gene mapping to gene function","volume":"24","author":"Tomer","year":"2003","journal-title":"Endocr Rev"},{"key":"R26-6-20241201","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.amjmed.2004.04.004","article-title":"Hepatitis C and thyroid autoimmunity: is there a link?","volume":"117","author":"Tomer","year":"2004","journal-title":"Am J Med"},{"key":"R27-6-20241201","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1111\/j.1365-2265.1995.tb01894.x","article-title":"The incidence of thyroid disorders in the community: a twenty\u2010year follow\u2010up of the Whickham survey","volume":"43","author":"Vanderpump","year":"1995","journal-title":"Clin Endocrinol (Oxf"},{"key":"R28-6-20241201","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/S0006-291X(88)81072-6","article-title":"Existence of anti\u2010thyroglobulin IgG in healthy subjects","volume":"155","author":"Kohno","year":"1988","journal-title":"Biochem Biophys Res Comm"},{"key":"R29-6-20241201","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/0090-1229(85)90146-1","article-title":"A high prevalence of thyroglobulin autoantibodies in adults with and without thyroid diesase as measured with a sensitive solid\u2010 phase immunosorbent radioassay","volume":"37","author":"Ericsson","year":"1985","journal-title":"Clinical Immunology and Immunopathology"},{"key":"R30-6-20241201","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1046\/j.1365-2265.2002.01553.x","article-title":"Thyrotoxicosis induced by alpha\u2010interferon therapy in chronic viral hepatitis","volume":"56","author":"Wong","year":"2002","journal-title":"Clin Endocrinol (Oxf"},{"key":"R31-6-20241201","doi-asserted-by":"crossref","first-page":"2155","DOI":"10.1016\/0016-5085(92)90348-3","article-title":"Development of thyroid disease during therapy of chronic viral hepatitis with interferon alfa","volume":"102","author":"Lisker\u2010Melman","year":"1992","journal-title":"Gastroenterology"},{"key":"R32-6-20241201","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1111\/j.1365-2265.1993.tb02423.x","article-title":"Reversibility of thyroid dysfunction induced by recombinant alpha interferon in chronic hepatitis C","volume":"39","author":"Baudin","year":"1993","journal-title":"Clin Endocrinol (Oxf"},{"key":"R33-6-20241201","first-page":"1925","article-title":"Long\u2010term outcome of interferon\u2010alpha\u2010induced thyroid autoimmunity and prognostic influence of thyroid autoantibody pattern at the end of treatment","volume":"86","author":"Carella","year":"2001","journal-title":"J Clin Endocrinol Metab"},{"key":"R34-6-20241201","first-page":"399","article-title":"The risk factor for development of thyroid disease during interferon\u2010alpha therapy for chronic hepatitis C","volume":"89","author":"Watanabe","year":"1994","journal-title":"Am J Gastroenterol"},{"key":"R35-6-20241201","first-page":"922","article-title":"Autoimmune endocrine disease induced by recombinant interferon\u2010alpha therapy for chronic active type C hepatitis","volume":"80","author":"Imagawa","year":"1995","journal-title":"J Clin Endocrinol Metab"},{"key":"R36-6-20241201","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1159\/000184606","article-title":"Longitudinal study of antibodies against thyroid in patients undergoing interferon\u2010alpha therapy for HCV chronic hepatitis","volume":"44","author":"Carella","year":"1995","journal-title":"Horm Res"},{"key":"R37-6-20241201","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1046\/j.1365-2265.1996.751768.x","article-title":"Thyroid autoimmune disorders in patients with chronic hepatitis C before and during interferon\u2010alpha therapy","volume":"44","author":"Marazuela","year":"1996","journal-title":"Clin Endocrinol (Oxf"},{"key":"R38-6-20241201","first-page":"49","article-title":"Hashimoto's disease during interferon\u2010alpha therapy in a patient with pre\u2010treatment negative anti\u2010thyroid autoantibodies and with the specific genetic susceptibility to the thyroid disease","volume":"22","author":"Martocchia","year":"2001","journal-title":"Neuro Endocrinol Lett"},{"key":"R39-6-20241201","doi-asserted-by":"crossref","first-page":"1745","DOI":"10.1345\/aph.1G144","article-title":"Hashimoto encephalopathy with pegylated interferon alfa\u20102b and ribavirin","volume":"39","author":"Deutsch","year":"2005","journal-title":"Ann Pharmacother"},{"key":"R40-6-20241201","doi-asserted-by":"crossref","first-page":"1972","DOI":"10.1172\/JCI26031","article-title":"Thyrotropin receptor\u2010associated diseases: from adenomata to Graves disease","volume":"115","author":"Davies","year":"2005","journal-title":"J Clin Invest"},{"key":"R41-6-20241201","doi-asserted-by":"crossref","first-page":"1468","DOI":"10.1056\/NEJM199311113292007","article-title":"Pathogenesis of Graves' ophthalmopathy","volume":"329","author":"Bahn","year":"1993","journal-title":"N Eng J Med"},{"key":"R42-6-20241201","first-page":"168","article-title":"Management of Graves' ophthalmopathy: reality and perspectives","volume":"21","author":"Bartalena","year":"2000","journal-title":"Endocr Rev"},{"key":"R43-6-20241201","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1007\/s10238-004-0026-3","article-title":"Thyroid autoimmunity and dysfunction associated with type I interferon therapy","volume":"3","author":"Monzani","year":"2004","journal-title":"Clin Exp Med"},{"key":"R44-6-20241201","first-page":"399","article-title":"Etiology, pathogenesis, and clinical aspects of thyroiditis","volume":"13","author":"Volpe","year":"1978","journal-title":"Pathol Annu"},{"key":"R45-6-20241201","first-page":"1","article-title":"Persistent thyroid autoimmunity after subacute thyroiditis","volume":"23","author":"Weetman","year":"1987","journal-title":"J Clin Lab Immunol"},{"key":"R46-6-20241201","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1046\/j.1365-2893.2000.00247.x","article-title":"Subacute thyroiditis during treatment with combination therapy (interferon plus ribavirin) for hepatitis C virus","volume":"7","author":"Parana","year":"2000","journal-title":"J Viral Hepat"},{"key":"R47-6-20241201","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/S0168-8278(96)80113-9","article-title":"Side effects of high\u2010dose interferon therapy for chronic hepatitis C","volume":"25","author":"Okanoue","year":"1996","journal-title":"J Hepatol"},{"key":"R48-6-20241201","first-page":"107","article-title":"Infection, Thyroid Disease and Autoimmunity","volume":"14","author":"Tomer","year":"1993","journal-title":"Endocr Rev"},{"key":"R49-6-20241201","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1007\/BF03343626","article-title":"Independent expression of serological markers of thyroid autoimmunity and hepatitis virus C infection in the general population: results of a community\u2010based study in north\u2010western Sardinia","volume":"22","author":"Loviselli","year":"1999","journal-title":"J Endocrinol Invest"},{"key":"R50-6-20241201","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1089\/thy.1997.7.421","article-title":"Failure to find an association between hepatitis C virus and thyroid autoimmunity","volume":"7","author":"Metcalfe","year":"1997","journal-title":"Thyroid"},{"key":"R51-6-20241201","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1016\/0168-8278(95)80216-9","article-title":"Prevalence of thyroid autoantibodies is not increased in blood donors with hepatitis C virus infection","volume":"22","author":"Boadas","year":"1995","journal-title":"J Hepatol"},{"key":"R52-6-20241201","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1002\/hep.1840180205","article-title":"High prevalence of thyroid autoantibodies in a prospective series of patients with chronic hepatitis C before interferon therapy","volume":"18","author":"Tran","year":"1993","journal-title":"HEPATOLOGY"},{"key":"R53-6-20241201","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1006\/jaut.1999.0360","article-title":"Latent autoimmune thyroiditis in untreated patients with HCV chronic hepatitis: a case\u2010control study","volume":"14","author":"Ganne\u2010Carrie","year":"2000","journal-title":"J Autoimmun"},{"key":"R54-6-20241201","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1001\/archinte.158.13.1445","article-title":"Increased risk of autoimmune thyroid disease in hepatitis C vs hepatitis B before, during, and after discontinuing interferon therapy","volume":"158","author":"Fernandez\u2010Soto","year":"1998","journal-title":"Arch Intern Med"},{"key":"R55-6-20241201","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.amjmed.2004.01.023","article-title":"Thyroid disorders in chronic hepatitis C","volume":"117","author":"Antonelli","year":"2004","journal-title":"Am J Med"},{"key":"R56-6-20241201","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/S0168-8278(05)80228-4","article-title":"Latent autoimmune thyroid disease in patients with chronic HCV hepatitis","volume":"17","author":"Pateron","year":"1993","journal-title":"J Hepatol"},{"key":"R57-6-20241201","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1111\/j.1365-2265.1977.tb01340.x","article-title":"The spectrum of thyroid disease in a community: the Whickham survey","volume":"7","author":"Tunbridge","year":"1977","journal-title":"Clin Endocrinol Oxf"},{"key":"R58-6-20241201","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1530\/eje.0.1460743","article-title":"The addition of ribavirin to interferon\u2010alpha therapy in patients with hepatitis C virus\u2010related chronic hepatitis does not modify the thyroid autoantibody pattern but increases the risk of developing hypothyroidism","volume":"146","author":"Carella","year":"2002","journal-title":"Eur J Endocrinol"},{"key":"R59-6-20241201","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1046\/j.1365-2796.2002.00974.x","article-title":"Thyroid dysfunction during treatment of chronic hepatitis C with interferon alpha: no association with either interferon dosage or efficacy of therapy","volume":"251","author":"Dalgard","year":"2002","journal-title":"J Intern Med"},{"key":"R60-6-20241201","first-page":"3290","article-title":"Linkage analysis of candidate genes in autoimmune thyroid disease: 2. Selected gender\u2010related genes and the X\u2010chromosome","volume":"83","author":"Barbesino","year":"1998","journal-title":"J Clin Endocrinol Metab"},{"key":"R61-6-20241201","first-page":"531","article-title":"Sex hormones, immune responses, and autoimmune diseases. Mechanisms of sex hormone action","volume":"121","author":"Ansar","year":"1985","journal-title":"Am J Pathol"},{"key":"R62-6-20241201","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1210\/jcem-61-4-735","article-title":"The genetics of Graves' disease: HLA and disease susceptibility","volume":"61","author":"Stenszky","year":"1985","journal-title":"J Clin Endocrinol Metab"},{"key":"R63-6-20241201","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1038\/sj.gene.6364059","article-title":"Arginine at position 74 of the HLA\u2010DRb1 chain is associated with Graves' disease","volume":"5","author":"Ban","year":"2004","journal-title":"Genes Immun"},{"key":"R64-6-20241201","first-page":"41","article-title":"CTLA\u20104 gene polymorphism associated with Graves' disease in a caucasian population","volume":"80","author":"Yanagawa","year":"1995","journal-title":"J Clin Endocrinol Metab"},{"key":"R65-6-20241201","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1093\/hmg\/8.7.1195","article-title":"The cytotoxic T lymphocyte antigen\u20104 is a major Graves' disease locus","volume":"8","author":"Vaidya","year":"1999","journal-title":"Hum Mol Genet"},{"key":"R66-6-20241201","first-page":"1687","article-title":"CTLA\u20104 and not CD28 is a susceptibility gene for thyroid autoantibody production","volume":"86","author":"Tomer","year":"2001","journal-title":"J Clin Endocrinol Metab"},{"key":"R67-6-20241201","doi-asserted-by":"crossref","first-page":"3020","DOI":"10.2337\/diabetes.53.11.3020","article-title":"Replication of an association between the lymphoid tyrosine phosphatase locus (LYP\/PTPN22) with type 1 diabetes, and evidence for its role as a general autoimmunity locus","volume":"53","author":"Smyth","year":"2004","journal-title":"Diabetes"},{"key":"R68-6-20241201","doi-asserted-by":"crossref","first-page":"5862","DOI":"10.1210\/jc.2004-1108","article-title":"The codon 620 tryptophan allele of the lymphoid tyrosine phosphatase (LYP) gene is a major determinant of Graves' disease","volume":"89","author":"Velaga","year":"2004","journal-title":"J Clin Endocrinol Metab"},{"key":"R69-6-20241201","doi-asserted-by":"crossref","first-page":"15119","DOI":"10.1073\/pnas.2434175100","article-title":"Amino acid substitutions in the thyroglobulin gene are associated with susceptibility to human and murine autoimmune thyroid disease","volume":"100","author":"Ban","year":"2003","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R70-6-20241201","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1016\/S0168-8278(99)80131-7","article-title":"HLA antigens in patients with interferon\u2010alpha\u2010induced autoimmune thyroid disorders in chronic hepatitis C","volume":"30","author":"Kakizaki","year":"1999","journal-title":"J Hepatol"},{"key":"R71-6-20241201","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1002\/hep.20819","article-title":"Consensus proposals for a unified system of nomenclature of hepatitis C virus genotypes","volume":"42","author":"Simmonds","year":"2005","journal-title":"HEPATOLOGY"},{"key":"R72-6-20241201","doi-asserted-by":"crossref","first-page":"2285","DOI":"10.1023\/A:1018870818662","article-title":"Hepatitis C serotypes in nonalcoholic and alcoholic patients","volume":"42","author":"Sherman","year":"1997","journal-title":"Dig Dis Sci"},{"key":"R73-6-20241201","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1002\/hep.510300131","article-title":"Hepatitis cRNA quasispecies complexity in patients with alcoholic liver disease","volume":"30","author":"Sherman","year":"1999","journal-title":"HEPATOLOGY"},{"key":"R74-6-20241201","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1086\/421506","article-title":"Complexity and diversity of hepatitis C virus RNA in African Americans and whites: analysis of the envelope\u2010coding domain","volume":"190","author":"Keenan","year":"2004","journal-title":"J Infect Dis"},{"key":"R75-6-20241201","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1530\/eje.0.1420431","article-title":"Virologic factors related to interferon\u2010alpha\u2010induced thyroid dysfunction in patients with chronic hepatitis C","volume":"142","author":"Hsieh","year":"2000","journal-title":"Eur J Endocrinol"},{"key":"R76-6-20241201","doi-asserted-by":"crossref","first-page":"488","DOI":"10.3748\/wjg.v11.i4.488","article-title":"Autoantibodies and hepatitis C virus genotypes in chronic hepatitis C patients in Estonia","volume":"11","author":"Zusinaite","year":"2005","journal-title":"World J Gastroenterol"},{"key":"R77-6-20241201","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1590\/S1413-86702003000600009","article-title":"Comparative study of hepatitis C virus genotypes 1 and 3 in Salvador, Bahia Brazil","volume":"7","author":"Codes","year":"2003","journal-title":"Braz J Infect Dis"},{"key":"R78-6-20241201","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1046\/j.1365-2265.1999.00686.x","article-title":"Prevalence and significance of thyroid autoantibodies in patients with chronic hepatitis C virus infection: a prospective controlled study","volume":"50","author":"Huang","year":"1999","journal-title":"Clin Endocrinol (Oxf"},{"key":"R79-6-20241201","first-page":"419","article-title":"[Natural history of dysthyroidism during interferon treatment of chronic hepatitis C]","volume":"57","author":"Mekkakia\u2010Benhabib","year":"1996","journal-title":"Ann Endocrinol (Paris"},{"key":"R80-6-20241201","doi-asserted-by":"crossref","first-page":"2081","DOI":"10.2174\/1381612043384330","article-title":"The role of ribavirin in the combination therapy of hepatitis C virus infection","volume":"10","author":"Picardi","year":"2004","journal-title":"Curr Pharm Des"},{"key":"R81-6-20241201","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1111\/j.1440-1746.2003.03329.x","article-title":"Ribavirin upregulates interleukin\u201012 receptor and induces T cell differentiation towards type 1 in chronic hepatitis C","volume":"19","author":"Shiina","year":"2004","journal-title":"J Gastroenterol Hepatol"},{"key":"R82-6-20241201","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1016\/S0168-8278(99)80093-2","article-title":"Ribavirin polarizes human T cell responses towards a Type 1 cytokine profile","volume":"30","author":"Tam","year":"1999","journal-title":"J Hepatol"},{"key":"R83-6-20241201","doi-asserted-by":"crossref","first-page":"3709","DOI":"10.4049\/jimmunol.163.7.3709","article-title":"Contact hypersensitivity responses following ribavirin treatment in vivo are influenced by type 1 cytokine polarization, regulation of IL\u201010 expression, and costimulatory signaling","volume":"163","author":"Tam","year":"1999","journal-title":"J Immunol"},{"key":"R84-6-20241201","doi-asserted-by":"crossref","first-page":"2381","DOI":"10.1099\/0022-1317-79-10-2381","article-title":"The antiviral compound ribavirin modulates the T helper (Th) 1\/Th2 subset balance in hepatitis B and C virus\u2010specific immune responses","volume":"79","author":"Hultgren","year":"1998","journal-title":"J Gen Virol"},{"key":"R85-6-20241201","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1089\/107999000750053690","article-title":"Biologic responses to IFN\u2010alpha administration in humans","volume":"20","author":"Corssmit","year":"2000","journal-title":"J Interferon Cytokine Res"},{"key":"R86-6-20241201","doi-asserted-by":"crossref","first-page":"2063","DOI":"10.1126\/science.1074900","article-title":"Critical role for STAT4 activation by type 1 interferons in the interferon\u2010gamma response to viral infection","volume":"297","author":"Nguyen","year":"2002","journal-title":"Science"},{"key":"R87-6-20241201","first-page":"61","article-title":"Expression of ICAM\u20101, B7.1 and TPO on human thyrocytes induced by IFN\u2010alpha","volume":"112","author":"You","year":"1999","journal-title":"Chin Med J (Engl"},{"key":"R88-6-20241201","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1111\/j.1365-2249.1997.269-ce1161.x","article-title":"Effects of interferon\u2010alpha (IFN\u2010alpha) administration on leucocytes in healthy humans","volume":"107","author":"Corssmit","year":"1997","journal-title":"Clin Exp Immunol"},{"key":"R89-6-20241201","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1007\/BF01714980","article-title":"Acute hematologic effects of interferon alpha, interferon gamma, tumor necrosis factor alpha and interleukin 2","volume":"62","author":"Aulitzky","year":"1991","journal-title":"Ann Hematol"},{"key":"R90-6-20241201","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1046\/j.1365-2249.1996.d01-784.x","article-title":"Intrathyroidal cytokine gene expression in Hashimoto's thyroiditis","volume":"105","author":"Ajjan","year":"1996","journal-title":"Clin Exp Immunol"},{"key":"R91-6-20241201","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1210\/jcem-70-6-1735","article-title":"Inhibition of 125I organification and thyroid hormone release by interleukin\u20101, tumor necrosis factor\u2010alpha, and interferon\u2010gamma in human thyrocytes in suspension culture","volume":"70","author":"Sato","year":"1990","journal-title":"J Clin Endocrinol Metab"},{"key":"R92-6-20241201","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1016\/S0002-9343(03)00390-5","article-title":"Autoimmune aspects of cytokine and anticytokine therapies","volume":"115","author":"Krause","year":"2003","journal-title":"Am J Med"},{"key":"R93-6-20241201","doi-asserted-by":"crossref","first-page":"2785","DOI":"10.1073\/pnas.70.10.2785","article-title":"Enhancement by interferon of the expression of surface antigens on murine leukemia L 1210 cells","volume":"70","author":"Lindahl","year":"1973","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R94-6-20241201","first-page":"1120","article-title":"Cytolytic T cells with Th1\u2010like cytokine profile predominate in retroorbital lymphocytic infiltrates of Graves' ophthalmopathy","volume":"77","author":"De Carli","year":"1993","journal-title":"J Clin Endocrinol Metab"},{"key":"R95-6-20241201","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1126\/science.7761837","article-title":"T helper cell subsets in insulin\u2010dependent diabetes","volume":"268","author":"Katz","year":"1995","journal-title":"Science"},{"key":"R96-6-20241201","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1016\/S0167-5699(00)01710-2","article-title":"Type I interferons and T helper development","volume":"21","author":"Farrar","year":"2000","journal-title":"Immunol Today"},{"key":"R97-6-20241201","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1053\/gast.1997.v112.pm9041265","article-title":"New insights into the mechanisms of interferon alfa: an immunoregulatory and anti\u2010inflammatory cytokine","volume":"112","author":"Tilg","year":"1997","journal-title":"Gastroenterology"},{"key":"R98-6-20241201","doi-asserted-by":"crossref","first-page":"4138","DOI":"10.1210\/jc.2005-0093","article-title":"Innate and acquired immune system in patients developing interferon\u2010alpha\u2010related autoimmune thyroiditis: a prospective study","volume":"90","author":"Mazziotti","year":"2005","journal-title":"J Clin Endocrinol Metab"},{"key":"R99-6-20241201","doi-asserted-by":"crossref","first-page":"3724","DOI":"10.1210\/en.2004-0352","article-title":"Signal transducer and activator of transcription (Stat)\u20106\u2010dependent, but not Stat4\u2010dependent, immunity is required for the development of autoimmunity in Graves' hyperthyroidism","volume":"145","author":"Land","year":"2004","journal-title":"Endocrinology"},{"key":"R100-6-20241201","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1046\/j.1365-2796.2002.01045.x","article-title":"Is the IFN\u2010alpha\u2010related thyroid autoimmunity an immunologically heterogeneous disease?","volume":"252","author":"Mazziotti","year":"2002","journal-title":"J Intern Med"},{"key":"R101-6-20241201","doi-asserted-by":"crossref","first-page":"3522","DOI":"10.4049\/jimmunol.170.7.3522","article-title":"Prevention of autoantibody\u2010mediated Graves'\u2010like hyperthyroidism in mice with IL\u20104, a Th2 cytokine","volume":"170","author":"Nagayama","year":"2003","journal-title":"J Immunol"},{"key":"R102-6-20241201","first-page":"161","article-title":"The effects of alpha interferon on the development of autoimmune thyroiditis in the NOD H2h4 mouse","volume":"10","author":"Oppenheim","year":"2003","journal-title":"Clin Dev Immunol"},{"key":"R103-6-20241201","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1210\/jc.2004-1173","article-title":"Type I interferons modulate the expression of thyroid peroxidase, sodium\/iodide symporter, and thyroglobulin genes in primary human thyrocyte cultures","volume":"90","author":"Caraccio","year":"2005","journal-title":"J Clin Endocrinol Metab"},{"key":"R104-6-20241201","first-page":"1439","article-title":"Reversible inhibition by interferons alpha and beta of 125I incorporation and thyroid hormone release by human thyroid follicles in vitro","volume":"77","author":"Yamazaki","year":"1993","journal-title":"J Clin Endocrinol Metab"},{"key":"R105-6-20241201","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1056\/NEJM200010263431707","article-title":"Graves' disease","volume":"343","author":"Weetman","year":"2000","journal-title":"N Engl J Med"}],"container-title":["Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fhep.21146","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.lww.com\/01515467-200604000-00006","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T07:06:44Z","timestamp":1733036804000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/01515467-200604000-00006"}},"subtitle":["Toward a new classification\u2020"],"short-title":[],"issued":{"date-parts":[[2006,4]]},"references-count":103,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2006]]}},"URL":"https:\/\/doi.org\/10.1002\/hep.21146","relation":{},"ISSN":["0270-9139"],"issn-type":[{"value":"0270-9139","type":"print"}],"subject":[],"published":{"date-parts":[[2006,4]]}}}